Targeting Cell Survival Proteins for Cancer Cell Death

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2016 Mar 2

PMID 26927133

Citations 18

Authors

Manoj K Pandey

Sahdeo Prasad

Amit Kumar Tyagi

Lokesh Deb

Jiamin Huang

Deepkamal N Karelia

Shantu G Amin

Bharat B Aggarwal

Affiliations

Soon will be listed here.

Abstract

Escaping from cell death is one of the adaptations that enable cancer cells to stave off anticancer therapies. The key players in avoiding apoptosis are collectively known as survival proteins. Survival proteins comprise the Bcl-2, inhibitor of apoptosis (IAP), and heat shock protein (HSP) families. The aberrant expression of these proteins is associated with a range of biological activities that promote cancer cell survival, proliferation, and resistance to therapy. Several therapeutic strategies that target survival proteins are based on mimicking BH3 domains or the IAP-binding motif or competing with ATP for the Hsp90 ATP-binding pocket. Alternative strategies, including use of nutraceuticals, transcriptional repression, and antisense oligonucleotides, provide options to target survival proteins. This review focuses on the role of survival proteins in chemoresistance and current therapeutic strategies in preclinical or clinical trials that target survival protein signaling pathways. Recent approaches to target survival proteins-including nutraceuticals, small-molecule inhibitors, peptides, and Bcl-2-specific mimetic are explored. Therapeutic inventions targeting survival proteins are promising strategies to inhibit cancer cell survival and chemoresistance. However, complete eradication of resistance is a distant dream. For a successful clinical outcome, pretreatment with novel survival protein inhibitors alone or in combination with conventional therapies holds great promise.

Citing Articles

Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors.

Zhang C, Cui S, Mu J, Liu K, Wang Y, Zhao H ACS Med Chem Lett. 2025; 16(2):301-310.

PMID: 39967617 PMC: 11831383. DOI: 10.1021/acsmedchemlett.4c00550.

The Potential Role of Exosomal Proteins in Prostate Cancer.

Feng S, Lou K, Zou X, Zou J, Zhang G Front Oncol. 2022; 12:873296.

PMID: 35747825 PMC: 9209716. DOI: 10.3389/fonc.2022.873296.

NUCKS1 is a highly modified, chromatin-associated protein involved in a diverse set of biological and pathophysiological processes.

Ostvold A, Grundt K, Wiese C Biochem J. 2022; 479(11):1205-1220.

PMID: 35695515 PMC: 10016235. DOI: 10.1042/BCJ20220075.

Impact of the phytochemicals cocktail "breast safeguard" in regulating the interplay between redox signalling and murine adenocarcinoma cell proliferation, survival and angiogenesis.

Abdraboh M, Daw D, AbouEl-Ezz A, El-Kholy W Heliyon. 2021; 7(7):e07562.

PMID: 34355084 PMC: 8322271. DOI: 10.1016/j.heliyon.2021.e07562.

Overcoming Hypoxia-Induced Chemoresistance in Cancer Using a Novel Glycoconjugate of Methotrexate.

Wozniak M, Pastuch-Gawolek G, Makuch S, Wisniewski J, Ziolkowski P, Szeja W Pharmaceuticals (Basel). 2020; 14(1).

PMID: 33374474 PMC: 7830245. DOI: 10.3390/ph14010013.

References

Kitada S, Leone M, Sareth S, Zhai D, Reed J, Pellecchia M . Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003; 46(20):4259-64. DOI: 10.1021/jm030190z. View

Verhagen A, Ekert P, Pakusch M, Silke J, Connolly L, Reid G . Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000; 102(1):43-53. DOI: 10.1016/s0092-8674(00)00009-x. View

Jhaveri K, Taldone T, Modi S, Chiosis G . Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2011; 1823(3):742-55. PMC: 3288123. DOI: 10.1016/j.bbamcr.2011.10.008. View

Sun J, Li Z, Hu Z, Zeng Z, Yang D, Jiang W . Apogossypolone inhibits cell growth by inducing cell cycle arrest in U937 cells. Oncol Rep. 2009; 22(1):193-8. DOI: 10.3892/or_00000424. View

Tzung S, Kim K, Basanez G, Giedt C, Simon J, Zimmerberg J . Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol. 2001; 3(2):183-91. DOI: 10.1038/35055095. View

Wang Z, Goulet 3rd R, Stanton K, Sadaria M, Nakshatri H . Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005; 25(3c):2367-79. View

Boise L, Gonzalez-Garcia M, Postema C, Ding L, LINDSTEN T, Turka L . bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74(4):597-608. DOI: 10.1016/0092-8674(93)90508-n. View

Opferman J, Letai A, Beard C, Sorcinelli M, Ong C, Korsmeyer S . Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003; 426(6967):671-6. DOI: 10.1038/nature02067. View

Levkau B, Garton K, Ferri N, Kloke K, Nofer J, Baba H . xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res. 2001; 88(3):282-90. DOI: 10.1161/01.res.88.3.282. View

10.

Caldas-Lopes E, Cerchietti L, Ahn J, Clement C, Robles A, Rodina A . Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009; 106(20):8368-73. PMC: 2688867. DOI: 10.1073/pnas.0903392106. View

11.

Biamonte M, Van de Water R, Arndt J, Scannevin R, Perret D, Lee W . Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010; 53(1):3-17. DOI: 10.1021/jm9004708. View

12.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

13.

Mohammad R, Goustin A, Aboukameel A, Chen B, Banerjee S, Wang G . Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007; 13(7):2226-35. DOI: 10.1158/1078-0432.CCR-06-1574. View

14.

Kolettas E, Thomas C, Leneti E, Skoufos I, Mbatsi C, Sisoula C . Rosmarinic acid failed to suppress hydrogen peroxide-mediated apoptosis but induced apoptosis of Jurkat cells which was suppressed by Bcl-2. Mol Cell Biochem. 2006; 285(1-2):111-20. DOI: 10.1007/s11010-005-9064-8. View

15.

Perciavalle R, Opferman J . Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol. 2012; 23(1):22-9. PMC: 3532576. DOI: 10.1016/j.tcb.2012.08.011. View

16.

Ling X, Cao S, Cheng Q, Keefe J, Rustum Y, Li F . A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One. 2012; 7(9):e45571. PMC: 3446924. DOI: 10.1371/journal.pone.0045571. View

17.

Margarucci L, Monti M, Cassiano C, Mozzicafreddo M, Angeletti M, Riccio R . Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor. Chem Commun (Camb). 2013; 49(52):5844-6. DOI: 10.1039/c3cc41858h. View

18.

Petersen S, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J . Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell. 2007; 12(5):445-56. PMC: 3431210. DOI: 10.1016/j.ccr.2007.08.029. View

19.

Bai L, Chen J, McEachern D, Liu L, Zhou H, Aguilar A . BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One. 2014; 9(6):e99404. PMC: 4047118. DOI: 10.1371/journal.pone.0099404. View

20.

Al-Karaawi M . Interaction studies to evaluate 2- carboxyphenolate analogues as inhibitor of anti-apoptotic protein Bcl-2. Bioinformation. 2013; 9(9):477-80. PMC: 3705619. DOI: 10.6026/97320630009477. View